276 related articles for article (PubMed ID: 28401446)
1. Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
Lamb YN; Scott LJ
Drugs; 2017 May; 77(7):785-792. PubMed ID: 28401446
[TBL] [Abstract][Full Text] [Related]
2. Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study.
Bang YJ; Li CP; Lee KH; Chiu CF; Park JO; Shan YS; Kim JS; Chen JS; Shim HJ; Rau KM; Choi HJ; Oh DY; Belanger B; Chen LT
Cancer Sci; 2020 Feb; 111(2):513-527. PubMed ID: 31789476
[TBL] [Abstract][Full Text] [Related]
3. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
4. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
Vogel A; Ciardiello F; Hubner RA; Blanc JF; Carrato A; Yang Y; Patel DA; Ektare V; de Jong FA; Gill S
Cancer Treat Rev; 2016 Nov; 50():142-147. PubMed ID: 27676174
[TBL] [Abstract][Full Text] [Related]
5. Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial.
Macarulla T; Blanc JF; Wang-Gillam A; Chen LT; Siveke JT; Mirakhur B; Chen J; de Jong FA
J Geriatr Oncol; 2019 May; 10(3):427-435. PubMed ID: 30842038
[TBL] [Abstract][Full Text] [Related]
6. Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.
Pelzer U; Blanc JF; Melisi D; Cubillo A; Von Hoff DD; Wang-Gillam A; Chen LT; Siveke JT; Wan Y; Solem CT; Botteman MF; Yang Y; de Jong FA; Hubner RA
Br J Cancer; 2017 May; 116(10):1247-1253. PubMed ID: 28350787
[TBL] [Abstract][Full Text] [Related]
7. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Wang-Gillam A; Li CP; Bodoky G; Dean A; Shan YS; Jameson G; Macarulla T; Lee KH; Cunningham D; Blanc JF; Hubner RA; Chiu CF; Schwartsmann G; Siveke JT; Braiteh F; Moyo V; Belanger B; Dhindsa N; Bayever E; Von Hoff DD; Chen LT;
Lancet; 2016 Feb; 387(10018):545-557. PubMed ID: 26615328
[TBL] [Abstract][Full Text] [Related]
8. Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
Frampton JE
Drugs; 2020 Jul; 80(10):1007-1018. PubMed ID: 32557396
[TBL] [Abstract][Full Text] [Related]
9. Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Fleeman N; Abdulla A; Bagust A; Beale S; Richardson M; Stainthorpe A; Boland A; Kotas E; McEntee J; Palmer D
Pharmacoeconomics; 2018 Mar; 36(3):289-299. PubMed ID: 29178025
[TBL] [Abstract][Full Text] [Related]
10. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
Wang-Gillam A; Hubner RA; Siveke JT; Von Hoff DD; Belanger B; de Jong FA; Mirakhur B; Chen LT
Eur J Cancer; 2019 Feb; 108():78-87. PubMed ID: 30654298
[TBL] [Abstract][Full Text] [Related]
11. The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy.
Passero FC; Grapsa D; Syrigos KN; Saif MW
Expert Rev Anticancer Ther; 2016 Jul; 16(7):697-703. PubMed ID: 27219482
[TBL] [Abstract][Full Text] [Related]
12. Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.
Chen LT; Siveke JT; Wang-Gillam A; Li CP; Bodoky G; Dean AP; Shan YS; Jameson GS; Macarulla T; Lee KH; Cunningham D; Blanc JF; Chiu CF; Schwartsmann G; Braiteh FS; Mamlouk K; Belanger B; de Jong FA; Hubner RA
Eur J Cancer; 2018 Dec; 105():71-78. PubMed ID: 30414528
[TBL] [Abstract][Full Text] [Related]
13. Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial.
Macarulla Mercadé T; Chen LT; Li CP; Siveke JT; Cunningham D; Bodoky G; Blanc JF; Lee KH; Dean A; Belanger B; Wang-Gillam A
Pancreas; 2020 Jan; 49(1):62-75. PubMed ID: 31856081
[TBL] [Abstract][Full Text] [Related]
14. nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients.
Ueno M; Nakamori S; Sugimori K; Kanai M; Ikeda M; Ozaka M; Furukawa M; Okusaka T; Kawabe K; Furuse J; Komatsu Y; Ishii H; Sato A; Shimizu S; Chugh P; Tang R; Ioka T
Cancer Med; 2020 Dec; 9(24):9396-9408. PubMed ID: 33099898
[TBL] [Abstract][Full Text] [Related]
15. Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel.
Surinach A; Phung T; Abdul-Rahim O; Khushman M
Curr Oncol; 2020 Apr; 27(2):e222-e225. PubMed ID: 32489272
[TBL] [Abstract][Full Text] [Related]
16. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.
Hubner RA; Cubillo A; Blanc JF; Melisi D; Von Hoff DD; Wang-Gillam A; Chen LT; Becker C; Mamlouk K; Belanger B; Yang Y; de Jong FA; Siveke JT
Eur J Cancer; 2019 Jan; 106():24-33. PubMed ID: 30458340
[TBL] [Abstract][Full Text] [Related]
17. 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
Assaf E; Verlinde-Carvalho M; Delbaldo C; Grenier J; Sellam Z; Pouessel D; Bouaita L; Baumgaertner I; Sobhani I; Tayar C; Paul M; Culine S
Oncology; 2011; 80(5-6):301-6. PubMed ID: 21778770
[TBL] [Abstract][Full Text] [Related]
18. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.
Yoo C; Kim KP; Jeong JH; Kim I; Kang MJ; Cheon J; Kang BW; Ryu H; Lee JS; Kim KW; Abou-Alfa GK; Ryoo BY
Lancet Oncol; 2021 Nov; 22(11):1560-1572. PubMed ID: 34656226
[TBL] [Abstract][Full Text] [Related]
19. Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).
Trouilloud I; Dupont-Gossard AC; Malka D; Artru P; Gauthier M; Lecomte T; Aparicio T; Thirot-Bidault A; Lobry C; Asnacios A; Manet-Lacombe S; Fein F; Dubreuil O; Landi B; Zaanan A; Bonnetain F; Taïeb J
Eur J Cancer; 2014 Dec; 50(18):3116-24. PubMed ID: 25454414
[TBL] [Abstract][Full Text] [Related]
20. Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience.
Bupathi M; Ahn DH; Wu C; Ciombor KK; Stephens JA; Reardon J; Goldstein DA; Bekaii-Saab T
Med Oncol; 2016 Apr; 33(4):37. PubMed ID: 26995224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
